Comparison of standard-of-care idecabtagene vicleucel and ciltacabtagene autoleucel in relapsed/refractory multiple myeloma
Last Updated: Friday, June 6, 2025
Researchers compared the safety, efficacy, and survival of patients with relapsed/refractory multiple myeloma treated with idecabtagene vicleucel (ide-cel) or ciltacabtagene autoleucel (cilta-cel). They found that cilta-cel demonstrated superior efficacy and survival compared with ide-cel, although there was a higher incidence of certain toxicities in the cilta-cel group.
Advertisement
News & Literature Highlights
